Makers of insulin delivery systems, Tandem Diabetes Care (NASDAQ:TNDM) and Insulet (NASDAQ:PODD), marked a contrasting stock ...

Insulet beats Q2 estimates with strong Omnipod growth and lifts 2025 revenue outlook on rising adoption and expanding global ...

Thanks to a series of equity and debt offerings, Insulet has managed to buy time in the race to expand its sales base and reach profitability before running out of cash. As of the end of December, ...

GAAP revenue reached $649.1 million in Q2 2025, beating estimates by 5.7% and growing 32.9% year over year. Gross margin (GAAP) expanded to 69.7%, while International Omnipod sales grew 45% (GAAP).

The proposal would introduce competitive bidding for insulin pumps and change how Medicare pays for durable medical equipment ...

Insulet stock surged Thursday after the insulin pump-maker walloped second-quarter forecasts and raised its sales guidance for the year.

Insulet (Nasdaq:PODD) shares ticked up before hours today on second-quarter results that came in ahead of the consensus ...

A mom got a $14,000 bill for her son's insulin pump after insurance didn't pay for it. The Enquirer got involved, and the claim was approved.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three ...

Chadwick shared, “For the third quarter, we expect total Omnipod revenue growth of 24% to 27% and total company growth of 22% to 25%.” For full year 2025, she stated, “We are raising our total Omnipod ...

Tandem Diabetes Care's Q2 2025 shows U.S. weakness, margin pressure, and rising competition, raising strategy concerns. See ...